OSTEOPORE LIMITED — Board/Management Information 2020

Nov 1, 2020

==> picture [130 x 44] intentionally omitted <==

ASX RELEASE│OSTEOPORE LIMITED

OSTEOPORE APPOINTS EX-RESMED FINANCE EXECUTIVE TO CFO POSITION

2 November 2020: Osteopore Limited (ASX: OSX) (“Osteopore” or the “Company”), a revenue generating medical technology company that has commercialised a range of patented 3D printed bioresorbable products, is pleased to announce the appointment of Carl Runde as Chief Financial Officer of the Company.

Mr Runde has more than twenty years of international medical device industry experience in corporate financial analysis, valuation modelling, and strategic business planning. Mr Runde was previously Vice President Finance – Corporate Systems and FP&A for ResMed (NYSE: RMD and ASX: RMD.AX), a leading medical device company providing cloud-connectable devices for the treatment of sleep apnea and other respiratory disorders. Mr Runde held executive finance positions at ResMed from 2003 to 2019, working within multiple divisions across the Asia Pacific. Most recently Mr Runde has completed his PhD and worked as an independent financial consultant for medical technology start-ups.

Based in Sydney, Mr Runde will oversee all financial operations of Osteopore with a focus on facilitating growth and ensuring the creation of sustainable stakeholder value. Mr Runde will also manage the Company’s Investor Relations and Corporate communications

Coinciding with Mr Runde’s appointment, Mr Geoff Pocock will transition from his executive role at Osteopore to a Non- Executive Director role over the coming months. Mr Pocock will remain as a member of Osteopore’s Board, and will assist in the transition of Mr Runde to become Osteopore’s new primary point of contact for Australian capital markets.

Welcoming Mr Runde to Osteopore, Osteopore’s CEO, Goh Khoon Seng, commented “Carls’ significant financial reporting and commercial expertise will be invaluable as Osteopore continues its business development and growth trajectory".

This announcement has been approved for release by the Board of Osteopore.

For more information please contact:

Geoff Pocock Carl Runde Executive Director Chief Financial Officer Osteopore Limited Osteopore Ltd +61 412 194 373 +61 400 118 017 geoff_pocock@osteopore.com carl_runde@osteopore.com

About Osteopore Limited

Osteopore Ltd is an Australian and Singapore based medical technology company commercialising a range of bespoke products specifically engineered to facilitate bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore Limited (ACN 630 538 957)│ASX:OSX│16 Ord Street, West Perth│+618 9482 0500│www.osteopore.com

==> picture [130 x 44] intentionally omitted <==

Osteopore's patent protected scaffolds are made from proprietary polymer formulations, that naturally dissolve overtime to leave only natural. healthy bone tissue, significantly reducing postsurgery complications that are commonly associated with permanent bone implants.

Forward Looking Statements

Statements contained in this release, particularly those regarding possible or assumed future performance, revenue, costs, dividends, production levels or rates, prices or potential growth of Osteopore Limited, are, or may be, forward looking statements. Such statements relate to future events and expectations and, as such, involve known and unknown risks and uncertainties. Actual results may differ materially from those expressed or implied by these forward-looking statements depending on a variety of factors.

Osteopore Limited (ACN 630 538 957)│ASX:OSX│16 Ord Street, West Perth│+618 9482 0500│www.osteopore.com